Search - tctmd.com

Displaying 21 - 40 of 41

Sort: Relevancy | Date

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Conference News SCAI 2018

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

L.A. McKeown

May 01, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Presentation ACC 2018

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Presenter: Brendan M. Everett

March 12, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

Shelley Wood

March 12, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

‘Nontraditional’ CAC, CRP, or ABI Risk Tools Not Recommended, Says USPSTF

Shelley Wood

January 17, 2018

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2017

Caitlin E. Cox

August 31, 2017

Presentation ESC 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

Presenter: Paul M. Ridker

August 27, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

Shelley Wood

August 18, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

Shelley Wood

July 03, 2017

CANTOS: Canakinumab Cuts MI, Stroke in Post-MI Patients With Elevated CRP

News Daily News

CANTOS: Canakinumab Cuts Combo of MI, Stroke, CV Death in Post-MI Patients With Elevated CRP

Todd Neale

June 22, 2017

News Conference News EAS 2017

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Yael L. Maxwell

April 25, 2017

Advertisement

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

CANTOS: Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

‘Nontraditional’ CAC, CRP, or ABI Risk Tools Not Recommended, Says USPSTF

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

TCTMD’s Top 10 Most Popular Stories for August 2017

Anti-Inflammatory Therapy with Canakinumab for Atherosclerotic Disease

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

TCTMD’s Top 10 Most Popular Stories for June 2017

CANTOS: Canakinumab Cuts Combo of MI, Stroke, CV Death in Post-MI Patients With Elevated CRP

Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content